Publications by authors named "Kenneth Villman"

Claim this Profile
O
Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer.
Sofia Palmér, Antonis Valachis, Henrik Lindman, Daniel Robert Smith, Åsa Wickberg, Kenneth Villman

J Natl Cancer Inst· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.
Heikki Joensuu, Judith Fraser, Hans Wildiers, Riikka Huovinen, Päivi Auvinen, Kenneth K Villman

JAMA Netw Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola, Minna Tanner, Kenneth Villman

J Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront Radiotherapy in Patients With Asymptomatic Incurable Rectal Cancer: A Retrospective Cohort Study.
Gabriel Jonsson, Louise Philipson, Kenneth Villman, Antonis Valachis

Anticancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1.
Paula Poikonen-Saksela, Henrik Lindman, Asgerdur Sverrisdottir, Per Edlund, Kenneth Villman

Acta Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
Heikki Joensuu, Judith Fraser, Hans Wildiers, Riikka Huovinen, Päivi Auvinen, Kenneth K Villman

JAMA Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe.
Åsa Wickberg, Göran Liljegren, Fredrika Killander, Henrik Lindman, Judith Bjöhle, Kenneth Villman

Eur J Surg Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
Alexios Matikas, Sara Margolin, Mats Hellström, Hemming Johansson, Nils-Olof Bengtsson, Kenneth Villman

Breast Cancer Res Treat· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola-Vuorinen, Minna Tanner, Kenneth Villman

JAMA Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to a. Levy et Al.
Asa Wickberg, Lars Holmberg, Hans-Olov Adami, Anders Magnuson, Kenneth Villman

J Clin Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sector resection with or without postoperative radiotherapy for stage I breast cancer: 20-year results of a randomized trial.
Asa Wickberg, Lars Holmberg, Hans-Olov Adami, Anders Magnuson, Kenneth Villman

J Clin Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola-Vuorinen, Minna Tanner, Kenneth Villman

Acta Oncol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NQO1 expression correlates inversely with NFκB activation in human breast cancer.
Maral Jamshidi, Jirina Bartkova, Dario Greco, Johanna Tommiska, Rainer Fagerholm, Kenneth Villman

Breast Cancer Res Treat· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola-Vuorinen, Minna Tanner, Kenneth Villman

J Clin Oncol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer.
Juliane Baumgart, Kerstin Nilsson, Anneli Stavreus-Evers, Kristiina Kask, Kenneth Villman

Am J Obstet Gynecol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Sara Margolin, Nils-Olof Bengtsson, Lena Carlsson, Per Edlund, Mats Hellstrøm, Kenneth Villman

Acta Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola-Vuorinen, Minna Tanner, Kenneth Villman

Lancet Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.
Henrik Lindman, Gunnar Aström, Johan Ahlgren, Kenneth Villman, Carl Blomqvist

Acta Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
Kenneth Villman, John F Ohd, Elisabet Lidbrink, Lena Malmberg, Birgitta Lindh

Eur J Cancer· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
Kenneth Villman, Johanna Sjöström, Reino Heikkilä, Ragnar Hultborn, Per Malmström

Acta Oncol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Kenneth Villman, Carl Blomqvist, Rolf Larsson, Peter Nygren

Anticancer Drugs· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Ephb2 and Ephb4 in breast carcinoma.
Qinghua Wu, Zhenhe Suo, Bjørn Risberg, Mats G Karlsson, Kenneth Villman

Pathol Oncol Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer on the Internet: the quality of Swedish breast cancer websites.
Elisabeth Nilsson-Ihrfelt, Marie-Louise Fjällskog, Carl Blomqvist, Johan Ahlgren, Per Edlund, Kenneth Villman

Breast· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
Kenneth Villman, Elisabeth Ståhl, Göran Liljegren, Ulf Tidefelt, Mats G Karlsson

Mod Pathol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The expression of EGFR family ligands in breast carcinomas.
Zhenhe Suo, Bjørn Risberg, Mats G Karlsson, Kenneth Villman, Eva Skovlund

Int J Surg Pathol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis